Ebvaciclib

Overview

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase ( CDK ) , with K i values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2 , CDK4 and CDK6 , respectively. PF-06873600 has potential antineoplastic activity.

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-114177
• CAS No.: 2185857-97-8
• Molecular Formula: C20H27F2N5O4S
• Molecular Weight: 471.52
• Purity: 99.91%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
• Availability: In-stock

Source

Original product source